The combination of DC based vaccines with immune checkpoint blockers (anti-CTLA-4 and anti-PD-1/PD-L1) showed an improved targeting and a successful eradication of CSCs in melanoma, GBM and bladder cancer models [159]. This evidence concerns the gene CTLA4 and melanoma.